Adenoassociated viral mediated persistant anti-vegf therapy for ovarian cancer
AssigneeCornell University
InventorsRonald G. Crystal, Arash Rafii Tabrizi
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.
Claims14
A method of treating ovarian cancer in a patient comprising administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.
The method of claim 8, wherein the AAV vector encoding an anti-VEGF antibody or antigen binding fragment thereof is administered via intraperitoneal injection.
An adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof for treating ovarian cancer in a patient.
Use of an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof for the preparation of a medicament for treating ovarian cancer.
Dependencies are inferred from the claim text.